{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004155","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.058748+00:00","generated_at":"2026-05-28T04:29:56.054974+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Standard BioTools CCO Jeremy Davis to depart Feb 1, 2025; severance details disclosed","bullets":["Jeremy Davis will step down as Chief Commercial Officer effective February 1, 2025, by mutual agreement.","Severance includes 12 months' base salary continuation of $441,000 plus 2024 bonus of $169,785.","Pro-rated target bonus of $21,264.65 and COBRA premium payments through Feb 2026 or earlier.","Outstanding unvested equity awards will receive 100% vesting acceleration, with performance-based awards at target.","Severance agreement to be filed with Q1 2025 10-Q; no replacement yet announced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004155","json":"https://secwatch.observer/filing/0000950170-25-004155.json","markdown":"https://secwatch.observer/filing/0000950170-25-004155.md","text":"https://secwatch.observer/filing/0000950170-25-004155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025004155/0000950170-25-004155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025004155/lab-20250103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:29:56.054974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67ca168fbe","claim":"Jeremy Davis departed as Chief Commercial Officer at STANDARD BIOTOOLS INC..","evidence_excerpt":"On January 3, 2025, Standard BioTools Inc. (the “Company”) and Jeremy Davis, the Company’s Chief Commercial Officer, mutually determined that Mr. Davis will no longer serve in such position, effective as of February 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025004155/0000950170-25-004155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}